New data reinforces AstraZeneca and Sanofi’s nirsevimab as effective RSV immunisation
Nirsevimab is the first investigational immunisation designed to protect all infants across the RSV season with a single dose
Read More
Tag: Nirsevimab
Positive topline results for nirsevimab in RSV
Monoclonal antibody reduced lower respiratory tract infections due to RSV in healthy infants
Read More
Sanofi’s RSV treatment nirsevimab awarded PIM status
PIM status was awarded on the basis of Phase IIb results of nirsevimab
Read More
Nirsevimab shows promise for long-term RSV protection
The monoclonal antibody is the first potential passive immunisation for infants to demonstrate sustained protection across the entire RSV season with a single dose
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
